ZA927329B - Injectable extended release formulations and methods - Google Patents
Injectable extended release formulations and methodsInfo
- Publication number
- ZA927329B ZA927329B ZA927329A ZA927329A ZA927329B ZA 927329 B ZA927329 B ZA 927329B ZA 927329 A ZA927329 A ZA 927329A ZA 927329 A ZA927329 A ZA 927329A ZA 927329 B ZA927329 B ZA 927329B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- extended release
- release formulations
- injectable extended
- injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76955591A | 1991-10-01 | 1991-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA927329B true ZA927329B (en) | 1994-03-24 |
Family
ID=25085803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA927329A ZA927329B (en) | 1991-10-01 | 1992-09-24 | Injectable extended release formulations and methods |
Country Status (4)
Country | Link |
---|---|
US (1) | US5352662A (xx) |
TW (1) | TW269638B (xx) |
YU (1) | YU87892A (xx) |
ZA (1) | ZA927329B (xx) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW282403B (xx) * | 1993-08-26 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US7833543B2 (en) * | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
KR100445087B1 (ko) * | 1996-01-11 | 2004-10-15 | 파마시아 앤드 업존 캄파니 | 수성서방성제제 |
US6051558A (en) * | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US20060025328A1 (en) * | 1997-05-28 | 2006-02-02 | Burns Patrick J | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7258869B1 (en) * | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
EP1064934A1 (en) * | 1999-06-30 | 2001-01-03 | Applied Research Systems ARS Holding N.V. | GRF-containing lyophilized pharmaceutical composition |
US6960346B2 (en) | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US8133507B2 (en) * | 2002-12-13 | 2012-03-13 | Durect Corporation | Oral drug delivery system |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GEP20094831B (en) | 2004-09-17 | 2009-11-25 | Durect Corp | Control release system |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
ES2643140T3 (es) * | 2005-12-22 | 2017-11-21 | Oakwood Laboratories L.L.C. | Sistema de suministro de liberación lenta sublimable y procedimiento de realización del mismo |
DK2020990T3 (da) | 2006-05-30 | 2010-12-13 | Intarcia Therapeutics Inc | Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem |
EP2049081B1 (en) | 2006-08-09 | 2012-11-14 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
DK2117521T3 (da) | 2006-11-03 | 2012-09-03 | Durect Corp | Transdermale indgivelsessystemer omfattende bupivacain |
CN101715340A (zh) | 2007-04-23 | 2010-05-26 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
CA2691531C (en) | 2007-06-22 | 2016-11-01 | Board Of Regents,The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
US8415401B2 (en) | 2007-12-06 | 2013-04-09 | Durect Corporation | Oral pharmaceutical dosage forms |
WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
CA2743789C (en) | 2008-11-16 | 2017-10-31 | Board Of Regents, The Univesity Of Texas System | Low viscosity highly concentrated suspensions |
JP5718925B2 (ja) | 2009-09-28 | 2015-05-13 | インターシア セラピューティクス,インコーポレイティド | 実質的な定常状態薬物送達の迅速な確立及び/又は停止 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
WO2016196851A2 (en) | 2015-06-03 | 2016-12-08 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
CL2016000217A1 (es) * | 2016-01-27 | 2016-07-01 | Farmacologia En Aquacultura Veterinaria Fav S A | Nueva composición veterinaria inyectable para la sincronización del desove en peces |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58172311A (ja) * | 1982-04-02 | 1983-10-11 | Kodama Kk | 持続性製剤及びその製法 |
ES8702440A1 (es) * | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
JPS61114676A (ja) * | 1984-11-09 | 1986-06-02 | Nec Corp | ブロツク符号化装置 |
DE3579911D1 (de) * | 1984-12-24 | 1990-10-31 | Sumitomo Pharma | Stabiles grf-praeparat. |
IL79681A (en) * | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
US4775659A (en) * | 1985-08-19 | 1988-10-04 | Eli Lilly And Company | Injectable semi-solid formulations |
ZA866218B (en) * | 1985-08-23 | 1988-03-30 | Lilly Co Eli | Injectable sustained release formulation |
US4977140A (en) * | 1985-08-23 | 1990-12-11 | Eli Lilly And Company | Injectable sustained release formulation |
US4784845A (en) * | 1985-09-16 | 1988-11-15 | American Cyanamid Company | Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs |
CA1257199A (en) * | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
SE457693B (sv) * | 1986-07-01 | 1989-01-23 | Drilletten Ab | Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas |
US4837381A (en) * | 1986-08-11 | 1989-06-06 | American Cyanamid Company | Compositions for parenteral administration and their use |
ES2039219T3 (es) * | 1986-08-11 | 1993-09-16 | American Cyanamid Company | Composiciones para administracion parenteral y su uso. |
US4857506A (en) * | 1987-01-12 | 1989-08-15 | American Cyanamid Company | Sustained release growth hormone compositions for parenteral administration and their use |
US4857505A (en) * | 1987-03-09 | 1989-08-15 | American Cyanamid Company | Sustained release compositions for parenteral administration and their use |
GB8725427D0 (en) * | 1987-10-30 | 1987-12-02 | Lilly Industries Ltd | Somatotropin formulations |
AU645003B2 (en) * | 1988-11-08 | 1994-01-06 | Takeda Chemical Industries Ltd. | Sustained release preparations |
-
1992
- 1992-02-29 YU YU87892A patent/YU87892A/sh unknown
- 1992-08-21 US US07/934,017 patent/US5352662A/en not_active Expired - Fee Related
- 1992-09-24 ZA ZA927329A patent/ZA927329B/xx unknown
- 1992-10-01 TW TW081107789A patent/TW269638B/zh active
Also Published As
Publication number | Publication date |
---|---|
YU87892A (sh) | 1995-12-04 |
US5352662A (en) | 1994-10-04 |
TW269638B (xx) | 1996-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA927329B (en) | Injectable extended release formulations and methods | |
GR3023258T3 (en) | 3-Aryl-4-hydroxy-delta3-dihydrofuranone and 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives | |
GB9121289D0 (en) | Composition and use | |
IL101290A0 (en) | Vaccine formulations | |
GB9207832D0 (en) | Formulations | |
HU9400190D0 (en) | Therapeutic compositions and methods | |
GB9106048D0 (en) | Vaccines | |
ZA921279B (en) | Substituted alpha-aminoaldehydes and derivatives | |
IL103275A0 (en) | Injectable extended release formulations and methods | |
GB9114526D0 (en) | Compositions and use thereof | |
SG59871G (en) | Controlled release compositions and use | |
ZA921137B (en) | Composition and use | |
EP0505941A3 (en) | Peptifluorin and neopeptifluorin | |
ZA925237B (en) | Substituted 1-phenyl-1-benzoylamino-5-aminopentanes their preparation and use | |
GB9116906D0 (en) | Composition and use | |
ZA922520B (en) | Sustained release capsule and formulations | |
ZA925260B (en) | 3-aryl-4-hydroxy-delta3-dihydrofuranone and 3-aryl-4-hydroxy-delta3-dihydrothiophenone | |
GB9212816D0 (en) | Vaccines and their uses | |
GB9114574D0 (en) | Compound and use | |
GB9108220D0 (en) | Compound preparation and use thereof | |
GB9118704D0 (en) | Stabilised composition and use | |
GB9105082D0 (en) | Formulations | |
GB9107669D0 (en) | Formulations | |
GB9105373D0 (en) | Formulations | |
GB9124661D0 (en) | Formulations |